IntegraGen

Equities

ALINT

FR0010908723

Biotechnology & Medical Research

Market Closed - Euronext Paris Other stock markets 09:23:12 2024-07-12 am EDT			5-day change	1st Jan Change
0.56 ^EUR	0.00%		0.00%	-37.36%

May. 01	IntegraGen SA Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	IntegraGen SA Reports Earnings Results for the Half Year Ended June 30, 2023	CI

IntegraGen : and GoPath Laboratories sign licensing agreement for miR-31-3p test in North America

January 09, 2018 at 12:19 pm EST

IntegraGen and GoPath Laboratories announced today the signing of a non-exclusive licensing agreement allowing GoPath to develop and provide a test based on IntegraGen's proprietary miR-31-3p biomarker to physicians in the United States and Canada. The test will complement GoPath's specialized molecular diagnostic testing portfolio for cancer and enable clinicians to identify metastatic colorectal cancer patients who have a higher likelihood of response to anti-EGFR therapy.

Click here to view press release.

IntegraGen SA published this content on 09 January 2018 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 09 January 2018 17:19:07 UTC.

Original documenthttp://www.integragen.com/press-releases/integragen-gopath-laboratories-sign-licensing-agreement-mir-31-3p-test-north-america

Public permalinkhttp://www.publicnow.com/view/B286F0A366FDCD509A07C332F7F29B3C28094A43

Latest news about IntegraGen

IntegraGen SA Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 30	CI
IntegraGen SA Reports Earnings Results for the Half Year Ended June 30, 2023	23-10-23	CI
IntegraGen SA Announces Revenue Results for the First Half of 2023	23-07-13	CI
IntegraGen Announces Unaudited Revenue Results for the Full Year 2022	23-01-13	CI
IntegraGen SA Reports Earnings Results for the Half Year Ended June 30, 2022	22-10-18	CI
IntegraGen SA Reports Earnings Results for the Half Year Ended September 30, 2022	22-10-18	CI
IntegraGen SA Reports Earnings Results for the Half Year Ended September 30, 2022	22-10-18	CI
IntegraGen SA Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-29	CI
IntegraGen SA Announces Earnings Result for the First Half of 2021	21-10-08	CI
Global markets live: Intel, Moderna, Burberry, Pfizer, SoftwareOne, Swisscom...	21-07-16
IntegraGen SA Announces Unaudited Turnover for the First Half of 2021	21-07-16	CI
Integragen Sa Reports Earnings Results for the Full Year Ended December 31, 2020	21-04-19	CI
OncoDNA SA completed the acquisition of 64.7% stake in IntegraGen SA for €9.4 million.	20-11-11	CI
Integragen Sa Reports Earnings Results for the Half Year Ended June 30, 2020	20-09-17	CI
IntegraGen Announces Unaudited Sales for the First Half of 2020	20-07-09	CI
OncoDNA SA signed an agreement to acquire IntegraGen SA for €14.5 million.	20-07-08	CI
U.S. Cancer Center to Use IntegraGen's MERCURY™ Cloud-Based Tool for Oncology Sequencing Data Interpretation and Reporting	20-03-26	CI
IntegraGen SA Announces Financial Results for the Half Year Ended June 30, 2018	18-09-19	CI
IntegraGen SA Announces Results of the Ability of miR-31-3p to Predict Response to Therapy for Patients with Metastatic Colorectal Cancer	18-09-04	CI
The SeqOIA Cooperative Health Group Selects Integragen as the Operator of its Sequencing Platform as Part of the France Genomic Medicine 2025 Plan	18-07-31	CI
IntegraGen SA Announces Earnings Results for the Year Ended Dec. 31, 2017; Provides Revenue Guidance for 2018	18-04-12	CI
IntegraGen Presents Positive Data from Liquid Biopsy Studies of Company’s Proprietary miRNAs during 2018 European Lung Cancer Conference	18-04-12	CI
IntegraGen SA Announces Global Distribution Agreement with Twist Bioscience Corp	18-02-14	CI
IntegraGen and GoPath Laboratories Sign Licensing Agreement for the Commercialization of Mir-31-3P Test in North America	18-01-09	CI
Integragen Sa Announces Results from an Analysis of miR-31-3p Expression in Tumor Samples from Patients Enrolled in the NEW EPOC Clinical Trial	17-10-09	CI

Chart IntegraGen

Duration

Period

More charts

Company Profile

IntegraGen specializes in researching and identifying genetic biomarkers and in developing and marketing molecular diagnostic products and services, primarily in the field of oncology. The group's activity is organized around two sectors: - supply of genomic research services: high-speed genotyping services, medium-speed genotyping services, and ultra-high-speed sequencing services for academic research institutions and pharmaceutical groups; - sales of diagnostic solutions. France accounts for 84.7% of net sales.

Sector

Biotechnology & Medical Research

Calendar

2024-10-16 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Diagnostics & Testing

	1st Jan change	Capi.
INTEGRAGEN	-37.36%	4.04M
EXACT SCIENCES CORPORATION	-37.33%	8.55B
GUARDANT HEALTH, INC.	+14.86%	3.8B
IOVANCE BIOTHERAPEUTICS, INC.	+7.38%	2.44B
BGI GENOMICS CO., LTD.	-25.96%	1.87B
VERACYTE, INC.	-17.30%	1.74B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+36.49%	1.19B
CAREDX, INC	+32.58%	830M
SEEGENE, INC.	-7.64%	711M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-18.37%	589M

Bio Diagnostics & Testing